1.Recent Advances in Toxoplasma gondii Immunotherapeutics.
Sherene Swee Yin LIM ; Rofina Yasmin OTHMAN
The Korean Journal of Parasitology 2014;52(6):581-593
Toxoplasmosis is an opportunistic infection caused by the protozoan parasite Toxoplasma gondii. T. gondii is widespread globally and causes severe diseases in individuals with impaired immune defences as well as congenitally infected infants. The high prevalence rate in some parts of the world such as South America and Africa, coupled with the current drug treatments that trigger hypersensitivity reactions, makes the development of immunotherapeutics intervention a highly important research priority. Immunotherapeutics strategies could either be a vaccine which would confer a pre-emptive immunity to infection, or passive immunization in cases of disease recrudescence or recurrent clinical diseases. As the severity of clinical manifestations is often greater in developing nations, the development of well-tolerated and safe immunotherapeutics becomes not only a scientific pursuit, but a humanitarian enterprise. In the last few years, much progress has been made in vaccine research with new antigens, novel adjuvants, and innovative vaccine delivery such as nanoparticles and antigen encapsulations. A literature search over the past 5 years showed that most experimental studies were focused on DNA vaccination at 52%, followed by protein vaccination which formed 36% of the studies, live attenuated vaccinations at 9%, and heterologous vaccination at 3%; while there were few on passive immunization. Recent progress in studies on vaccination, passive immunization, as well as insights gained from these immunotherapeutics is highlighted in this review.
Drug Discovery/trends
;
Global Health
;
Humans
;
Immunization/*methods
;
Immunotherapy/*methods/trends
;
Protozoan Vaccines/immunology/isolation & purification
;
Toxoplasma/*immunology
;
Toxoplasmosis/*therapy
2.New Molecules in Babesia gibsoni and Their Application for Diagnosis, Vaccine Development, and Drug Discovery.
The Korean Journal of Parasitology 2014;52(4):345-353
Babesia gibsoni is an intraerythrocytic apicomplexan parasite that causes piroplasmosis in dogs. B. gibsoni infection is characterized clinically by fever, regenerative anemia, splenomegaly, and sometimes death. Since no vaccine is available, rapid and accurate diagnosis and prompt treatment of infected animals are required to control this disease. Over the past decade, several candidate molecules have been identified using biomolecular techniques in the authors' laboratory for the development of a serodiagnostic method, vaccine, and drug for B. gibsoni. This review article describes newly identified candidate molecules and their applications for diagnosis, vaccine production, and drug development of B. gibsoni.
Animals
;
Antigens, Protozoan/*diagnostic use/*immunology
;
Antiprotozoal Agents/*isolation & purification/pharmacology
;
Babesia/*drug effects/immunology/*isolation & purification
;
Babesiosis/*diagnosis/drug therapy/prevention & control
;
Dogs
;
Drug Discovery/methods
;
Protozoan Vaccines/*immunology
3.Protective effect of lectin from Synadenium carinatum on Leishmania amazonensis infection in BALB/c mice.
Sandra R AFONSO-CARDOSO ; Flavio H RODRIGUES ; Marcio AB GOMES ; Adriano G SILVA ; Ademir ROCHA ; Aparecida HB GUIMARAES ; Ignes CANDELORO ; Silvio FAVORETO ; Marcelo S FERREIRA ; Maria A SOUZA
The Korean Journal of Parasitology 2007;45(4):255-266
The protective effect of the Synadenium carinatum latex lectin (ScLL), and the possibility of using it as an adjuvant in murine model of vaccination against American cutaneous leishmaniasis, were evaluated. BALB/c mice were immunized with the lectin ScLL (10, 50, 100 microgram/animal) separately or in association with the soluble Leishmania amazonensis antigen (SLA). After a challenge infection with 10(6) promastigotes, the injury progression was monitored weekly by measuring the footpad swelling for 10 weeks. ScLL appeared to be capable of conferring partial protection to the animals, being most evident when ScLL was used in concentrations of 50 and 100 microgram/animal. Also the parasite load in the interior of macrophages showed significant reduction (61.7%) when compared to the control group. With regard to the cellular response, ScLL 50 and 100 microgram/animal stimulated the delayed-type hypersensitivity (DTH) reaction significantly (P < 0.05) higher than SLA or SLA plus ScLL 10 weeks after the challenge infection. The detection of high levels of IgG2a and the expression of mRNA cytokines, such as IFN-gamma, IL-12, and TNF-alpha (Th1 profiles), corroborated the protective role of this lectin against cutaneous leishmaniasis. This is the first report of the ScLL effect on leishmaniasis and shows a promising role for ScLL to be explored in other experimental models for treatment of leishmaniasis.
*Adjuvants, Immunologic
;
Animals
;
Antibodies, Protozoan/immunology
;
Antibody Formation
;
Antigens, Protozoan/immunology
;
Cytokines/genetics/immunology
;
Euphorbiaceae/*chemistry
;
Hypersensitivity, Delayed/immunology
;
Immunization
;
Immunoglobulin G/immunology
;
Latex/chemistry
;
Leishmania/immunology
;
Leishmaniasis, Cutaneous/*immunology/pathology
;
Mice
;
Mice, Inbred BALB C
;
Nitric Oxide Synthase Type II/genetics/immunology
;
Plant Lectins/*immunology/isolation & purification
;
Protozoan Vaccines/immunology/pharmacology
;
Skin/pathology